To include your compound in the COVID-19 Resource Center, submit it here.

Kicking RCC in the GLUT

A Stanford University School of Medicine team has identified a compound that blocked the growth of renal cell carcinomas in mice by inhibiting GLUT1, a protein involved in a metabolic pathway unique to the tumors.1 The inhibitor is exclusively licensed to Ruga Corp., which now is optimizing the compound.

Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults. The disease often is

Read the full 660 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers